Skip to main content

Table 3 Tumour size and the impact on endocrine function in the study population (n = 101) at baseline and after TSS

From: Post-operative volumes following endoscopic surgery for non-functioning pituitary macroadenomas are predictive of further intervention, but not endocrine outcomes

Preoperative tumour volume Males (n = 62) Females (n = 39) p-value
 Mean tumour size (cm3) ± SD 8.88 ± 8.56 6.46 ± 5.05 0.12
Age at surgery (years) 59.3 ± 13.3 0.35
Individual hormone axis Mean tumour size (cm3) p-value
  • GH deficiency 8.45 ± 6.10 0.44
  • LH/FSH deficiency 8.81 ± 8.92 0.22
  • ACTH deficiency 7.17 ± 5.34 0.45
  • TSH deficiency 7.88 ± 6.41 0.93
Number of pituitary hormone deficiencies
 • 0 6.28 ± 4.18 0.69
 • 1–2 9.00 ± 9.88
 • ≥3 7.92 ± 5.91
Postoperative Tumour Residuum
 Mean tumour residuum size (cm3) ± SD 1.96 ± 4.46
Number of pituitary hormone deficiencies Mean tumour size (cm3) p-value
  • 0 1.68 ± 2.29 0.44
  • 1–2 2.34 ± 6.39
  • ≥ 3 1.24 ± 2.07
Extent of Resection (EOR)
  Mean EOR (%) ± SD 75.9 ± 21.8; Range: 3.4–100%
  Gross total resection (GTR) 7 (6.9%)
  Near total resection (≥90 % ) 28 (27.7%), including 7 GTR
  Subtotal resection (75–89.9%) 39 (38.6%)
  Partial resection (< 75%) 30 (29.7%)
Endocrine outcomes Mean EOR (%) ± SD p-value
  • New axis deficit (n = 25) 78.6 ± 23.5 0.48
  • Axis recovery (n = 16) 79.9 ± 16.9 0.45
  • Pituitary function preserved (n = 60) 73.8 ± 22.1 0.38
  1. The effects of the extent of tumour resection are studied on the appearance of new hormone deficits and on axis recovery. A p-value of < 0.05 is considered statistically significant